Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
One study found that about 67% of patients taking Structure Therapeutics’s pill lost over 6% of their weight and about 33% ...
Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable weight-loss medication Wegovy. The Power of Wegovy highlights the individual results ...
FAT jabs could be the cancer hope of the future after early studies found they reduce the risk of tumours. The world’s top experts are preparing for a research boom to find out if the wonder drugs ...
Investors interested in the pharmaceutical industry are currently excited about the anti-obesity market. Weight-loss ...
The study looked at whether people on Wegovy maintained their weight loss. Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...
A couple of new scientific studies on Ozempic were just published. Both indicate that the medicine could be useful in treating addiction. Novo Nordisk just started a new clinical trial to clarify the ...
(Reuters) - Britain's medical costs regulator on Tuesday recommended Eli Lilly's weight-loss drug Mounjaro for some patients with obesity and suggested not placing a time limit on the medicine's use ...
Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is ...
The company reported $175.8 million in sales of Zepbound in the first few weeks of its launch in December. The drug, chemically known as tirzepatide, has been available as Mounjaro for type 2 diabetes ...
Structure Therapeutics said on Monday its experimental oral obesity drug helped reduce weight by 6.2% on average in a mid-stage study, exceeding Wall Street expectations and sending shares 20% higher ...